Details for Patent: 10,646,550
✉ Email this page to a colleague
Which drugs does patent 10,646,550 protect, and when does it expire?
Patent 10,646,550 protects VOXZOGO and is included in one NDA.
This patent has thirty patent family members in seventeen countries.
Summary for Patent: 10,646,550
| Title: | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
| Abstract: | The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component. |
| Inventor(s): | Bullens; Sherry (Novato, CA), Bunting; Stuart (Novato, CA), Chou; Tianwei (Novato, CA), Okhamafe; Augustus O. (Concord, CA), Price; Christopher P. (Munich, DE), Wendt; Daniel J. (Novato, CA), Yap; Clarence (Novato, CA) |
| Assignee: | BioMarin Pharmaceutical Inc. (Novato, CA) |
| Application Number: | 15/880,002 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 10,646,550
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | |||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | |||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,646,550
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 105563 | ⤷ Try a Trial | |||
| Australia | 2016298425 | ⤷ Try a Trial | |||
| Australia | 2023200669 | ⤷ Try a Trial | |||
| Brazil | 112018001761 | ⤷ Try a Trial | |||
| Canada | 2994280 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
